Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson’s disease

Parkinson’s disease (PD) is associated with increased iron levels in the substantia nigra (SNc). This study evaluated whether the iron chelator, deferiprone, is well tolerated, able to chelate iron from various brain regions and improve PD symptomology. In a randomised double-blind, placebo controll...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Sci Rep
Main Authors: Martin-Bastida, Antonio, Ward, Roberta J., Newbould, Rexford, Piccini, Paola, Sharp, David, Kabba, Christina, Patel, Maneesh C., Spino, Michael, Connelly, John, Tricta, Fernando, Crichton, Robert R., Dexter, David T.
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5431100/
https://ncbi.nlm.nih.gov/pubmed/28469157
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-017-01402-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados